Recent Updates
Recently added Catalysts
OM Positive Sentiment

Outset Medical to Present at the 44th Annual J.P. Morgan Healthcare Conference

Key Takeaway: Outset Medical, Inc. will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. CEO Leslie Trigg will discuss the company's innovative dialysis technology, the Tablo® Hemodialysis System, which is designed to reduce costs and complexity in dialysis care. The system is FDA-cleared and has been adopted by over 1,000 healthcare facilities in the U.S.
Price reaction · baseline $3.8 (2026-01-05 close) · hit pre-market · clean, no other OM news in the window
day 0 close
+12.9%
day 1
+14.2%
day 3 · peak
+20%

Market Sentiment Analysis

POSITIVE FACTORS

  • Outset Medical is pioneering innovative dialysis technology.
  • The company is presenting at a prestigious healthcare conference.
  • The Tablo® Hemodialysis System is FDA-cleared and widely trusted.
  • Outset is committed to improving patient care and operational outcomes.

Full Press Release Details

SAN JOSE, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that Chair & CEO Leslie Trigg will present at the 44thannual J.P. Morgan Healthcare conference on Wednesday, January 14, 2026, at 4:30 p.m. Pacific time.
A live and archived webcast of the presentation will be available on the “Investors” section of the Outset website athttps://investors.outsetmedical.com/.
About Outset Medical, Inc.Outset is a medical technology company transforming the dialysis experience across the continuum of care with a first-of-its-kind technology. The Tablo® Hemodialysis System, FDA-cleared for use from hospital to home, is trusted by more than 1,000 U.S. healthcare facilities and has enabled millions of treatments delivered by thousands of nurses. Designed to reduce the cost and complexity of dialysis, Tablo combines water purification and on-demand dialysate production into a single, integrated system that connects seamlessly with Electronic Medical Record systems and a proprietary data analytics platform. This enterprise solution empowers providers to develop an in-house dialysis program where they are in control – enabling better operational, clinical, and financial outcomes. Outset is redefining what’s possible in kidney care through innovation, scale, and a relentless commitment to improving the lives of patients and the professionals who care for them. For more information, visitwww.outsetmedical.com.

ContactJim MazzolaVice President, Investor Relationsjmazzola@outsetmedical.com

Frequently Asked Questions

When will Outset Medical present at the conference?

Outset Medical will present on January 14, 2026, at 4:30 p.m. Pacific time.

What technology will Outset Medical discuss?

Outset Medical will discuss its Tablo® Hemodialysis System, designed to improve dialysis care.

Where can I watch the presentation?

The presentation will be available via a live and archived webcast on Outset's website.

What is the significance of the Tablo® System?

The Tablo® System is FDA-cleared and trusted by over 1,000 U.S. healthcare facilities.

Last updated: Jan 6, 2026